Form 4: Director McKenna Boosts NAMS Stake with RSU and Option Grants

NewAmsterdam Pharma Director Mark C. McKenna received grants of 3,400 restricted stock units and options for 15,300 ordinary shares.

Summary

• Director Mark C. McKenna of NewAmsterdam Pharma Company N.V. (NAMS) was granted 3,400 restricted stock units (RSUs) and options to purchase 15,300 ordinary shares on January 7, 2026.
• The RSUs represent a contingent right to receive one ordinary share each and will vest on the one-year anniversary of the vesting start date, subject to continued service.
• The options have an exercise price of $35.45 per share and will vest on January 2, 2027, which is the one-year anniversary of the vesting start date, also subject to continued service.
• Following these transactions, McKenna beneficially owns 10,360 ordinary shares and 15,300 options.
• Both the RSUs and options were granted for no consideration.

Sentiment

Score: 7

Explanation: The filing reports routine equity compensation for a director, which is generally positive as it aligns management incentives with shareholder interests. No negative events are reported.

Positives

• Director Mark C. McKenna received a significant grant of 3,400 restricted stock units (RSUs) and options for 15,300 ordinary shares, aligning his interests with shareholders.
• The grants are part of compensation, indicating continued commitment and incentivization for the director's long-term service to the company.

Negatives

• No direct negatives are present in this Form 4 filing, as it primarily reports compensation grants.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The vesting schedules for the restricted stock units and options indicate a future commitment from the director, with vesting contingent on continued service through January 2, 2027, for options and the one-year anniversary of the vesting start date for RSUs.

Management Comments

• No notable quotes or paraphrased statements from company management are included in this Form 4 filing.

Industry Context

These equity grants are a standard practice in the pharmaceutical and biotechnology industry for executive and director compensation, aiming to align leadership interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• Equity compensation packages, including restricted stock units and stock options with vesting schedules tied to continued service, are common across the pharmaceutical and biotech sectors.
• The specific grant amounts and exercise prices would typically be benchmarked against peer companies of similar market capitalization and development stage, though this filing does not provide such comparative data.

Stakeholder Impact

• Shareholders: The grants incentivize the director to work towards increasing shareholder value, as the value of the RSUs and options is tied to the company's stock performance.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The restricted stock units will vest on the one-year anniversary of their vesting start date, subject to the director's continued service.
• The options will vest on January 2, 2027, subject to the director's continued service.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a director, which is a standard practice to align management incentives with shareholder interests. It does not contain information that would fundamentally alter the investment thesis for NewAmsterdam Pharma Company N.V. Therefore, a 'hold' recommendation is appropriate, as the filing itself does not provide new catalysts for a 'buy' or 'sell' decision, but rather confirms ongoing corporate governance and compensation practices.

Keywords

NewAmsterdam Pharma, NAMS, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Director Compensation, Equity Grant